Collaboration on Novel Protein


Ivrea/Paris - Nautilus Biotech SA (France) and Creabilis Therapeutics SRL (Italy) recently signed a collaboration agreement for the identification and development of an improved variant of CT500, a non-antibody protein selected by Creabilis Therapeutics, with antagonist activity against HMGB1. HMGB1 is a DNA-binding chemo-cytokine that due to its key - and in some cases causative - role in several pathological conditions has become a relevant drug target in recent years. The new anti-HMGB1-variant protein, object of the agreement, is expected to have potential applications in various acute and chronic clinical indications such as autoimmune diseases, infective diseases, sepsis, tumours, cardiovascular and also neurologic and amyloid pathologies.
Nautilus' proprietary technology for protein evolution based on systematic mutagenesis, which is already successfully applied to a number of well-known thera-peutic proteins, will be used to improve the pharmacodynamic profile of CT500. The terms of the agreement have not been disclosed.
Manuel Vega, CEO of Nautilus Biotech comments: “So far our technology has been applied to marketed proteins, such as
IFN- and IFN- , to improve them by single point aminoacid substitution to create new products with highly competitive PK/PD characteristics compared to the marketed counterparts. This agreement allows us to apply the same methodology to a novel protein at a very early stage of development. It is a good demonstration of the flexibility of our approach that can be used to improve lead proteins right after the discovery phase.”
“We are most confident”, said Creabilis Therapeutic's CEO Silvano Fumero, “that Nautilus' technology will enable us to obtain an improved candidate drug with higher and competitive pharmacological and clinical potential.”



Milan – Everyone agrees that Italy is not Greece, but it is common wisdom that the country could also be doing better. Considering the meagre growth of the Italian economy in the last decade however, data fom the 2011 survey of...



Milan – Italian drugmaker Newron Pharmaceuticals S.p.A. and Merck Serono have broadened the scope of their 5-year-old collaboration on CNS drugs. In addition to the Parkinson’s treatment safinamide, under the terms of a new...



Milan/Berlin – Swiss-Italian biotech Philogen SpA has revoked its plan to sell a 23% stake worth EUR65.3m and go public on the Milan stock exchange this Friday. The move came after German Bayer HealthCare unexpectedly terminated...



Rome – The EUR2.5m ERC Advanced Grants are the Grammies of European science – not in the same league as a Nobel Prize, but still a lucrative honor. In the fourth round since 2007, the European Research Council awarded some a590m...



Modena/London – Researchers from Germany, Italy and the UK have identified a molecule that is key to the onset of addiction and also involved into memory formation (EMBO Journal, doi:10.1038/emboj.2010.279). According to results...



Genoa/Philadelphia — The inexpensive anti-gout drug allopurinol can counteract colorectal adenoma progression, according to data presented yesterday at the 9th Annual AACR Frontiers in Cancer Prevention Research Conference...

Displaying results 11 to 20 out of 181

< Previous 11-20 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • CYTOS0.66 CHF6.45%
  • EVOLVA1.84 CHF5.14%
  • EPIGENOMICS5.55 EUR4.52%


  • MEDIGENE8.43 EUR-3.77%
  • WILEX3.95 EUR-2.47%
  • BASILEA132.00 CHF-2.08%


  • 4SC4.65 EUR257.7%
  • SYNGENTA430.80 CHF31.8%
  • EVOLVA1.84 CHF21.1%


  • CYTOS0.66 CHF-35.3%
  • MEDIGENE8.43 EUR-30.7%
  • CO.DON2.85 EUR-17.4%


  • WILEX3.95 EUR393.7%
  • 4SC4.65 EUR322.7%
  • FORMYCON28.39 EUR311.4%


  • MOLOGEN5.05 EUR-53.4%
  • BIOFRONTERA2.29 EUR-24.9%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.05.2015

Current issue

All issues